Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Sektion für Stammzell- und Immuntherapie > Publikationen / Publications > 2005 - 2009

Publikationen / Publications

2009

Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. Peipp, M., Dechant, M., und Valerius, T. MAbs. (2009), 1(6): S. 590-9. (PubMed)

CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. Meyer, D., Seth, S., Albrecht, J., Maier, M.K., du Pasquier, L., Ravens, I., Dreyer, L., Burger, R., Gramatzki, M., Schwinzer, R., Kremmer, E., Foerster, R., und Bernhardt, G. J Biol Chem. (2009), 284(4): S. 2235-44. (PubMed)

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Burger, R., Le Gouill, S., Tai, Y.T., Shringarpure, R., Tassone, P., Neri, P., Podar, K., Catley, L., Hideshima, T., Chauhan, D., Caulder, E., Neilan, C.L., Vaddi, K., Li, J., Gramatzki, M., Fridman, J.S., und Anderson, K.C. (2009), Mol Cancer Ther. 8(1): S. 26-35. (PubMed)

Serum-free production and purification of chimeric IgA antibodies. Beyer, T., Lohse, S., Berger, S., Peipp, M., Valerius, T., und Dechant, M. J Immunol Methods. (2009),  346(1-2): S. 26-37. (PubMed)

2008

Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. Peipp, M., Schneider-Merck, T., Dechant, M., Beyer, T., Lammerts van Bueren, J.J., Bleeker, W.K., Parren, P.W., van de Winkel, J.G., und Valerius, T. J Immunol. (2008), 180(6): S. 4338-45. (PubMed)

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Peipp, M., Lammerts van Bueren, J.J., Schneider-Merck, T., Bleeker, W.W., Dechant, M., Beyer, T., Repp, R., van Berkel, P.H., Vink, T., van de Winkel, J.G., Parren, P.W., und Valerius, T. Blood. (2008), 112(6): S. 2390-9. (PubMed)

T cell-specific siRNA delivery suppresses HIV-1 infection in a humanized mouse model. Kumar, P., Ban, H.S., Kim, S.S., Wu, H., Pearson, T., Greiner, D.L., Laouar, A., Yao, J., Habiro, K., Yang, J.G., Jeong, J.H., Lee, K.Y., Kim, Y.H., Kim, S.W., Peipp, M., Fey, G.H., Shultz, L.D., Lee, S.K., und Shankar, P. Cell. (2008), 134: S577-586. (PubMed)

Effector mechanisms of therapeutic antibodies against ErbB receptors. Peipp, M., Dechant, M., und Valerius, T. Curr Opin Immunol. (2008), 20(4): S. 436-43. (PubMed)

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Horton, H.M., Bernett, M.J., Pong, E., Peipp, M., Karki, S., Chu, S.Y., Richards, J.O., Vostiar, I., Joyce, P.F., Repp, R., Desjarlais, J.R., und Zhukovsky, E.A. Cancer Res. (2008), 68(19): S. 8049-57. (PubMed)

Successful autologous hematopoietic progenitor cell transplantation in a patient with an isoantibody against CD36 (glycoprotein IV, Naka). Flesch, B., Miller, J., Repp, R., Ott, S., Gahn, B., Schub, N., Gramatzki, M., und Humpe, A. Bone Marrow Transplant. (2008), 42(7): S. 489-91. (PubMed)

Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J.J., Bleeker, W.K., Parren, P.W., van de Winkel, J.G., und Valerius, T. Cancer Res. (2008), 68(13): S. 4998-5003. (PubMed)

Novel CD19-directed recombinant bispecific antibody derivatives with enhanced immune effector functions for human leukaemic cells and prolonged in vivo retention. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH   J Immunother. (2008), 31(9): S. 871-84.  (PubMed)

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kugler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dorrie J, Ferrone S, Kampgen E, Fey GH Melanoma Res. (2008), 18: S. 73-84. (PubMed)

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W. Cancer Immunol Immunother. (2008), 57: S. 233-246. (PubMed)

2007

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M., und Voll, R.E. Cancer Res. (2007), 67(4): S. 1783-92. (PubMed)

Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Loffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermuller, J., Kretzschmar, A.K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., Cvijic, H., Ullmann, A.K., Stadler, P.F., und Horn, F. Blood. (2007), 110(4): S. 1330-3. (PubMed)

Cryopreservation of cellular products in a closed-bag system with an incorporated dimethyl sulfoxide-resistant sterile filter outside of cleanroom facilities. Humpe, A., Jansen, P., Tischer, B.K., Schubert, S., Beck, C., Adamzik, I.D., Maas, J.H., Strate, A., Gramatzki, M., und Riggert, J. Transfusion. (2007), 47(6): S. 1033-41. (PubMed)

Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. Dechant, M., Beyer, T., Schneider-Merck, T., Weisner, W., Peipp, M., van de Winkel, J.G., und Valerius, T. J Immunol. (2007) 179(5): S. 2936-43. (PubMed)

2006

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Schwemmlein, M., Peipp, M., Barbin, K., Saul, D., Stockmeyer, B., Repp, R., Birkmann, J., Oduncu, F., Emmerich, B., und Fey, G.H. Br J Haematol. (2006), 133(2): S. 141-51. (PubMed)

Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. Pachnio, A., Dietrich, S., Klapper, W., Humpe, A., Schwake, M., Sedlacek, R., Gramatzki, M., und Beck, C. Bone Marrow Transplant. (2006), 38(2): S. 157-67. (PubMed)

Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. Hoffmann, C., Repp, R., Schoch, R., Gahn, B., Schub, N., Beck, C., Humpe, A., Kneba, M., Horst, H.A., Schmitz, N., und Gramatzki, M. Eur J Med Res. (2006), 11(2): S. 73-6. (PubMed)

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC. Br J Haematol (2006), 134 (2): S. 145-156 (PubMed)

2005

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M., Stieglmaier, K., Niethammer, D., Stockmeyer, B., Peipp, M., Repp, R., Valerius, T., und Fey, G.H. Br J Haematol. (2005), 130(2): S. 218-28. (PubMed)

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Bremer, E., Samplonius, D.F., Peipp, M., van Genne, L., Kroesen, B.J., Fey, G.H., Gramatzki, M., de Leij, L.F., und Helfrich, W. (2005). Cancer Res. (2005), 65(8): S. 3380-8. (PubMed)

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC. Clin Cancer Res. (2005), 11 (11): S. 4251-4258. (PubMed)

A clinically relevant SCID-hu in vivo model of human multiple myeloma. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC. Blood. (2005(, 106 (2): S. 713-716. (PubMed)

Patupilone (Epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC. Blood. (2005), 105 (1): S. 350-357. (PubMed)